



ASX Announcement

20 February 2025

Wellnex Life Limited secures conditional binding commitments for \$14.3 million to meet the Company's estimated minimum capital requirement for the proposed dual listing on AIM

Announcement Highlights:

- The Company is targeting an AIM listing in early March 2025.
- Use of funds: Redeem the balance of the convertible notes (minus any conversions), pay the outstanding deferred consideration for the Pain Away acquisition, and the costs of the AIM listing and Entitlement Offer.
- The Company is expecting further commitments. If you are interested, please see contacts at bottom of announcement
- "This can be a game changing moment for WNX; we have a strong business growing quickly, expanding globally and expecting to be unencumbered by debt." - Joint Managing Director, Zack Bozinovski.

Wellnex Life Limited (ASX: WNX) is pleased to announce that, after receiving significant interest from both UK and Australian based institutions and sophisticated investors, it has received conditional binding commitments of \$14.3 million at \$0.65 per share, reaching the Company's estimated minimum amount of capital required in connection with the proposed listing on the AIM Market of the London Stock Exchange (AIM). These commitments are conditional on completion of the AIM listing.

Zack Bozinovski, Joint Managing Director of Wellnex Life said

"Securing what the Board estimates to be the minimum capital requirement to dual list on AIM is a great achievement for Wellnex Life. The proposed admission to AIM, once achieved, will not only save the company \$1.4 million in costs through the elimination of circa \$12.8 million in debt, but it will also provide increased exposure and credibility to the Company as it launches its brands into the European market. This follows the UK launch, with Haleon, of our innovative liquid paracetamol soft gel. Wellnex Life has a strong brand and product portfolio, and with a strengthened balance sheet, I am confident that it will have the necessary platform from which to grow revenues and margins."

The proposed dual listing of Wellnex Life on AIM remains subject to, *inter alia*, the Company meeting all regulatory requirements for admission, along with the successful completion of the conditional capital raise. Consequently completion of the AIM listing is not guaranteed.

Entitlement Offer

As announced to the ASX on 10 February 2025, the Company is inviting shareholders to participate in the non-renounceable pro-rata Entitlement Offer of one (1) New Share for every one (1) Share held at the Record Date of 13 February 2025, at an Issue Price of \$0.65 per New Share (Offer).

Shareholders can request an electronic copy of their personalised Entitlement Offer application form at - <https://wellnexlife.investorportal.com.au/request-form/>

WELLNEX

The closing date for the Offer is Wednesday 26 February 2025, at 5pm (AEDT).

Reach Markets are the advisers managing the Offer and can be contacted on 1300 805 795 or via advisers@reachmarkets.com.au

Shareholders (other than Directors and related parties of the Company) may subscribe for **Additional Shares** beyond their entitlement of 1 for 1 on the basis that some existing shareholders may be either ineligible (non-Australian or New Zealand residents) or may fail to fully take up their Entitlement. This additional ability is restricted only to eligible holders and is referred to as a **Top-Up Facility**.

Join a briefing

Join Managing Director of Wellnex Zack Bozinovski for a live and interactive shareholder briefing where he will discuss the Entitlement Offer, use of funds and how to participate.

Click here to register for a session:

<https://wellnexlife.investorportal.com.au/live-shareholder-briefing/>

About Wellnex Life

Wellnex is a growing and diverse consumer healthcare business that has spent the past years building a strong portfolio of own brands and licensing deals including own developed brands Wakey Wakey and Nighty Night, leading topical pain relief brand Pain Away (acquired in 2023) and IP licensing agreements with domestic and global pharmaceutical companies, including Haleon.

Wellnex Life continues to positively progress discussion with key partners to expand both its IP arrangements and brands beyond their current distribution territories (including the expansion of the product portfolio) into Europe and the Middle East. Wellnex Life will provide updates to shareholders as discussions progress and are finalized.

These efforts are now bearing fruit, with revenues growing over 112% in H1 FY25 versus the prior comparative period including revenue from Wellnex Life's brands up 182% and IP licensing up 64% for the same period. Wellnex Life under the global extension of the Haleon arrangement has delivered its first product for the UK market.

	July – Dec 2023	July – Dec 2024	% Change
Brands	\$3.0 million	\$8.47 million	182%
IP Licensing	\$2.12 million	\$3.47 million	64%
Brokerage	\$0.51 million	\$0	N/A
Total	\$5.63 million	\$11.94 million	112%

Wellnex Life's global ambitions, particularly the successful collaboration with Haleon – one of the largest consumer health companies in the world and listed on the London Stock Exchange – sparked the Company's proposal of a dual listing on AIM, which is part of one of the world's most respected public exchanges, the London Stock Exchange.

To stay up to date on company news and announcements, please register your details on the Wellnex Life Limited investor portal: <https://wellnexlife.investorportal.com.au/register/>



This announcement was authorised for release to the market by the board of Wellnex Life Limited.

For further information, please contact:

George Karafotias

T: +61 3 8399 9419

E: george.k@wellnexlife.com.au

**Reach Markets (Lead Manager-
Entitlement Offer)**

T: 1300 805 795

E: IR@reachmarkets.com.au

For shortfall enquiries

Patrick.Nelson@reachcorporate.com.au

Michael@barclaypearce.com.au

IMPORTANT INFORMATION

This announcement is issued by Wellnex Life. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Wellnex in any jurisdiction. This announcement does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of entitlements or fully paid ordinary shares in Wellnex Life. Nothing contained in this document constitutes investment, legal, tax or other advice. The information in this announcement is general information only, and does not take into account your individual objectives, taxation position, financial situation or needs. If you are unsure of your position, please contact your accountant, tax advisor, stockbroker or other professional advisor.

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any person in the United States or in any other jurisdiction in which such an offer would be illegal. No action has been or will be taken to register, qualify or otherwise permit a public offering of the New Shares under the Entitlement Offer in any jurisdiction outside Australia and New Zealand. In particular, the New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933 as amended (U.S. Securities Act) or under the securities laws of any state or other jurisdiction of the United States. The New Shares may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.